J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website https://www.jocmr.org

Original Article

Volume 13, Number 10-11, November 2021, pages 497-501

Effect of Treatment With Sodium-Glucose Cotransporter 2 Inhibitor on the Initiation of Continuous Positive Airway Pressure Therapy in Type 2 Diabetic Patients With Obstructive Sleep Apnea Syndrome

**Table 1.** Patient Characteristics at Baseline
Group	SGLT2 inhibitor	Non-SGLT2 inhibitor
SGLT2: sodium-glucose cotransporter 2; BMI: body mass index; HbA1c: hemoglobin A1c; DPP4: dipeptidyl peptidase 4; SD: standard deviation. Data are expressed as means ± SD.
n	9	7
Male/female	7/2	7/0
Age (years)	59 ± 12	55 ± 9
Body weight (kg)	80.2 ± 17.1	90.3 ± 13.4
BMI (kg/m²)	28.0 ± 5.4	29.5 ± 3.6
HbA1c (%)	6.9 ± 0.5	7.1 ± 0.7
Concomitant medication
Antidiabetic drug (n)
DPP4 inhibitor	8	4
Biguanide	6	2
Sulfonylurea	1	1
alpha-glucosidase inhibitor	1	1
Thiazolidinedione	4	2
Lipid-modifying agents (n)	9	2
Antihypertensive drug (n)	1	4

Table 1. Patient Characteristics at Baseline

Group

SGLT2 inhibitor

Non-SGLT2 inhibitor

SGLT2: sodium-glucose cotransporter 2; BMI: body mass index; HbA1c: hemoglobin A1c; DPP4: dipeptidyl peptidase 4; SD: standard deviation. Data are expressed as means ± SD.

Male/female

7/2

7/0

Age (years)

59 ± 12

55 ± 9

Body weight (kg)

80.2 ± 17.1

90.3 ± 13.4

BMI (kg/m²)

28.0 ± 5.4

29.5 ± 3.6

HbA1c (%)

6.9 ± 0.5

7.1 ± 0.7

Concomitant medication

Antidiabetic drug (n)

DPP4 inhibitor

Biguanide

Sulfonylurea

alpha-glucosidase inhibitor

Thiazolidinedione

Lipid-modifying agents (n)

Antihypertensive drug (n)

**Table 2.** Effects of SGLT2 Inhibitors on Various Parameters in Type 2 Diabetic Patients With OSAS
	SGLT2 inhibitor group (n = 9)	Non-SGLT2 inhibitor group (n = 7)
Data are expressed as means ± SD. P < 0.05, *P < 0.01 vs. before CPAP therapy. Days of CPAP: days of performed per month. SGLT2: sodium-glucose cotransporter 2; OSAS: obstructive sleep apnea syndrome; CPAP: continuous positive airway pressure; BMI: body mass index; HbA1c: hemoglobin A1c; AST: aspartate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyl transpeptidase; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; AHI: apnea-hypopnea index
Age (years)	59 ± 12		55 ± 9
Body weight (kg)	80.2 ± 17.1	81.9 ± 17.8**	90.3 ± 13.4	91.3 ± 14.1
BMI (kg/m²)	28.0 ± 5.4	28.6 ± 5.7**	29.5 ± 3.6	29.8 ± 3.8
HbA1c (%)	6.9 ± 0.5	7.1 ± 0.6	7.1 ± 0.69	7.0 ± 0.6
AST (U/L)	23.2 ± 8.6	24.4 ± 9.3	25.9 ± 5.8	27.1 ± 8.2
ALT (U/L)	30.6 ± 20.2	30 ± 17.4	31.4 ± 7.9	32.9 ± 10.9
γ-GTP (U/L)	28.4 ± 12.3	27.6 ± 10.8	44.4 ± 27.6	43.1 ± 28.4
Uric acid (mg/dL)	5.2 ± 0.9	5.1 ± 0.8	6.4 ± 0.8	6.3 ± 1.2
Total cholesterol (mg/dL)	182 ± 36	182 ± 29	192 ± 33	196 ± 36
HDL-C (mg/dL)	56 ± 19	54 ± 19	57 ± 9	53 ± 8
LDL-C (mg/dL)	102 ± 26	98 ± 18	112 ± 27	118 ± 35
Triglycerides (mg/dL)	169 ± 72	233 ± 106	152 ± 44	174 ± 103
AHI (events/h)	34.0 ± 19.3	1.9 ± 2.2**	44.2 ± 19.4	1.9 ± 0.9**
Days of CPAP (days/month)		26 ± 2		27 ± 1

Table 2. Effects of SGLT2 Inhibitors on Various Parameters in Type 2 Diabetic Patients With OSAS

SGLT2 inhibitor group (n = 9)

Non-SGLT2 inhibitor group (n = 7)

Before CPAP therapy

3 months after CPAP therapy

Before CPAP therapy

3 months after CPAP therapy

Data are expressed as means ± SD. *P < 0.05, **P < 0.01 vs. before CPAP therapy. Days of CPAP: days of performed per month. SGLT2: sodium-glucose cotransporter 2; OSAS: obstructive sleep apnea syndrome; CPAP: continuous positive airway pressure; BMI: body mass index; HbA1c: hemoglobin A1c; AST: aspartate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyl transpeptidase; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; AHI: apnea-hypopnea index

Age (years)

59 ± 12

55 ± 9

Body weight (kg)

80.2 ± 17.1

81.9 ± 17.8**

90.3 ± 13.4

91.3 ± 14.1

BMI (kg/m²)

28.0 ± 5.4

28.6 ± 5.7**

29.5 ± 3.6

29.8 ± 3.8

HbA1c (%)

6.9 ± 0.5

7.1 ± 0.6

7.1 ± 0.69

7.0 ± 0.6

AST (U/L)

23.2 ± 8.6

24.4 ± 9.3

25.9 ± 5.8

27.1 ± 8.2

ALT (U/L)

30.6 ± 20.2

30 ± 17.4

31.4 ± 7.9

32.9 ± 10.9

γ-GTP (U/L)

28.4 ± 12.3

27.6 ± 10.8

44.4 ± 27.6

43.1 ± 28.4

Uric acid (mg/dL)

5.2 ± 0.9

5.1 ± 0.8

6.4 ± 0.8

6.3 ± 1.2

Total cholesterol (mg/dL)

182 ± 36

182 ± 29

192 ± 33

196 ± 36

HDL-C (mg/dL)

56 ± 19

54 ± 19

57 ± 9

53 ± 8

LDL-C (mg/dL)

102 ± 26

98 ± 18

112 ± 27

118 ± 35

Triglycerides (mg/dL)

169 ± 72

233 ± 106

152 ± 44

174 ± 103

AHI (events/h)

34.0 ± 19.3

1.9 ± 2.2**

44.2 ± 19.4

1.9 ± 0.9**

Days of CPAP (days/month)

26 ± 2

27 ± 1